HBC is delighted to announce the hiring of Dr Tanja Schaffer as Executive Vice President of the Global Ingredients Division of HBC and as CEO of HBC’s new Swiss subsidiary, HBC Switzerland GmbH.
Setting up in Switzerland is part of HBC’s international strategy, Switzerland being widely recognized as a major center for biotechnology and life sciences. A presence in Switzerland will benefit HBC’s partnerships with major global players based in the country and allow HBC to provide opportunities for talented and experienced professionals to engage with HBC outside of Norway.
The operations of HBC Switzerland GmbH will initially provide services to HBC related to marketing, sales and organizational development, and HBC is delighted to have Dr Schaffer assume the role of CEO and lead the development of HBC Switzerland operations alongside. the development of the global ingredients business.
Dr. Schaffer is a highly accomplished business leader with over 15 years of experience in the commercialization of scientific ingredients. She started her career as head of the scientific department of Lipoid GmbH after obtaining her doctorate in physical chemistry at the University of Regensburg in Germany. Subsequently, she joined AllessaChemie as Head of Business Development, then was quickly promoted to Director of Marketing and Business Development before joining DKSH in 2011. For the past seven years, she has held the position of Vice- president of the global pharmaceutical industry at DKSH, where she was responsible for 26 global sales teams, four sourcing teams and several application labs. It should be noted that she was also responsible for the Animal Nutrition line with the Performance Materials division of DKSH as well as nutraceuticals in various Asian markets. As such, she brings a wealth of both technical know-how and knowledge and business relationships to help develop HBC’s business.
Dr Tanja Schaffer says: “I am very happy to join the great team at Hofseth Biocare and have the opportunity to further develop the market for innovative, sustainable and scientific products from HBC. I look forward to being part of the dynamic team and bringing the science of HBC to market. I believe the product has enormous market potential to be sold globally through multiple channels in food applications and medical nutrition. ”
Dr. Schaffer’s leadership is now part of a broader strategy to market and develop the branded ingredients sector, strategically located in Switzerland, geographically located at the center of Europe and a world capital for life sciences , food and ingredients. There is huge potential to grow sales of sustainable human grade ingredients in several categories including clinical nutrition, women’s health and fertility, gastrointestinal health, and sports nutrition. Unique and natural anti-inflammatory and antioxidant effects are now all the more desirable after the Covid-19 pandemic and future work will continue to show the differentiation processes of HBC products. The shift in sales from commodity feed markets to the higher value added human and companion animal supplement market will accelerate in 2022.
HBC has been targeted in its recruitment for top human talent from leading global pharmaceutical and nutraceutical companies to support its strategy. DKSH itself is a major part of a specialty distributor B2B strategy with HBC to give it global reach to brands it wouldn’t otherwise touch. The addition of Dr. Schaffer will also help catalyze this existing relationship even further.
Roger Hofseth says: “Hiring Tanja Schaffer is an amazing opportunity for HBC, and we are delighted to have him with us. Hiring a top executive directly from one of the world’s largest global ingredients market expansion teams, with such specialized product knowledge and sales experience, is a testament to the opportunity that HBC offers its customers. She will not only help develop our own branded formulations and provide more in-depth technical expertise, but will also focus on selling unique health claims with an unmatched sustainability profile. Her deep understanding of what Ingredients customers are looking for will help us grow our sales and further strengthen a close relationship with DKSH itself, which itself is purely focused on opening markets in Asia for us. His position will also help catalyze the excellent partnership with IMCD in Europe and the Americas to expand our reach globally.
For more information, please contact: James Berger CCO at Hofseth BioCare ASA Telephone: +41 79 950 1034 Email: [email protected]
About Hofseth BioCare ASA: HBC is a Norwegian biotechnology company that develops high value ingredients and finished products currently targeting the consumer health market. Research is underway to identify the individual elements in products that modulate inflammation and the immune response with preclinical studies in several clinics and academic research laboratories in several countries. The main clinical and preclinical candidates are under development for the protection of the gastrointestinal (GI) system against inflammation, including ulcerative colitis and necrotizing enterocolitis, an orphan disease, as a medical food to help for treating age-related sarcopenia, and as a drug for treating iron deficiency anemia, all using peptide fractions of salmon protein hydrolyzate. Preclinical trial work with the oil is underway to improve lung inflammation in eosinophilic asthma and COPD (“smoker’s lung”) as well as clinical work on COVID.
The company is founded on the fundamental values of sustainability and optimal use of natural resources. Using innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon scraps.
Hofseth BioCare’s head office is located in Ålesund, Norway, with branches in Oslo, London, Zurich, Chicago, Mumbai, Palo Alto and Tokyo. HBC is listed on the Oslo Stock Exchange under the symbol “HBC”. More information about Hofseth BioCare on www.hofsethbiocare.com
This information is subject to disclosure requirements in accordance with Section 5-12 of the Norwegian Securities Law.